8-K: Sera Prognostics Presents Promising Data on PreTRM Test at J.P. Morgan Healthcare Conference

Sera Prognostics highlights the clinical and economic benefits of its PreTRM test for predicting preterm birth in an investor presentation.

Summary

• Sera Prognostics presented an investor presentation on January 13, 2025, focusing on the PreTRM test and its impact on preterm birth prediction.
• The PreTRM test is designed to identify women at higher risk of spontaneous preterm delivery through a single blood draw during weeks 18-20 of gestation.
• Clinical studies, including the AVERT PRETERM Trial and the PRIME Trial, have demonstrated the test's ability to reduce neonatal hospital length of stay and severe neonatal morbidity and mortality.
• The AVERT study showed an 18% reduction in severe neonatal morbidity and mortality and a reduction in neonatal hospital length of stay by one week.
• The PRIME trial demonstrated statistically significant reductions in neonatal length of stay and neonatal morbidity index.
• An Elevance claims data analysis of over 40,000 mothers and babies showed a 20% reduction in preterm birth rates, a 10% reduction in neonatal intensive care admissions, and a 7% reduction in overall hospital length-of-stay with the PreTRM test-and-treat strategy.
• The company's strong balance sheet, with approximately $75 million in cash, is expected to support commercialization efforts into 2027.
• Sera Prognostics is focused on driving commercial inflection through publications, reimbursement guidelines, regulatory approvals, and additional evidence generation.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Sera Prognostics, highlighting the clinical and economic benefits of the PreTRM test and the company's strong financial position. The results of the AVERT and PRIME trials are promising, and the company is focused on driving commercial adoption.

Positives

• The PreTRM test has demonstrated clinical utility in multiple studies, including the PAPR Study, AVERT PRETERM Trial, and PRIME Trial.
• The test has shown significant reductions in neonatal hospital length of stay and severe neonatal morbidity and mortality.
• The Elevance cost-effectiveness model demonstrated robust clinical and economic impacts of the PreTRM test-and-treat strategy.
• Sera Prognostics has a strong balance sheet with sufficient cash to support commercialization efforts.
• The company is focused on obtaining reimbursement guidelines and regulatory approvals to drive commercial adoption.

Risks

• Forward-looking statements involve substantial risks and uncertainties, and actual results may differ materially.
• The company's success depends on achieving commercial inflection through publications, reimbursement guidelines, regulatory approvals, and additional evidence generation.
• ACOG is conservative with their approach to recommending novel diagnostics.

Future Outlook

Sera Prognostics aims to drive commercial inflection through publications, reimbursement guidelines, regulatory approvals, and additional evidence generation, supported by its strong cash position.

Industry Context

The presentation highlights the significant clinical and economic burden of preterm birth and positions PreTRM as a solution to improve outcomes and reduce costs. It also references ACOG guidelines and the importance of guideline inclusion for commercial success.

Comparison to Industry Standards

• The document compares the Number Needed to Screen (NNS) for PreTRM to prevent NICU admissions to other established tests.
• Transvaginal Ultrasound Cervical Length + Progesterone has an NNS of 150.
• Glucose Testing has an NNS of 50.
• PreTRM has an NNS of 40 to prevent NICU admission and ~4 to prevent 1 NICU day, suggesting a more efficient screening approach.

Stakeholder Impact

• Shareholders: Positive impact due to potential for increased revenue and market share.
• Patients: Improved outcomes and reduced risk of preterm birth complications.
• Payers: Potential cost savings due to reduced NICU admissions and hospital length of stay.
• Healthcare providers: A new tool to identify and manage patients at risk of preterm birth.

Next Steps

• Publications of PRIME and AVERT trial results.
• Awareness campaigns to educate providers and empower mothers.
• Engagement with SMFM leadership.
• Development of PreTRM champions.
• Review when evidence is sufficient for recommendation.
• Health Economics publication.
• RWE study publication.
• GRADE assessment of evidence.

Key Dates